ERGIC1

Across TCGA pan-cancer cohorts, ERGIC1 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ERGIC1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ERGIC1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ERGIC1 is over-expressed in tumor, although a few such as LSCC and HNSC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where ERGIC1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERGIC1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+1.049	<.001	12	view →
LUAD	Female	II,III,IV	+0.686	<.001	9	view →
LSCC	All	II,III,IV	−0.283	<.001	8	view →
HNSC	All	II,III,IV	−0.216	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ERGIC1–CCRCC

Open the CCRCC breakdown →